Central Bank & Trust’s Quest Diagnostics DGX Stock Holding History

Central Bank & Trust’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7	Closed	-$990	–	350
2023 Q1	$990	Buy	+7	New	+$1K	﹤0.01%	381

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Central Bank & Trust's DGX Position: Q2 2023 in Review

Central Bank & Trust sold out of Quest Diagnostics (DGX) in Q2 2023, closing a stake of 7 shares — an estimated $990 sold.

Central Bank & Trust first reported a position in DGX in Q1 2023 and held it in 1 quarter. The position peaked at $990 in Q1 2023. 818 funds tracked by Wall St. Rank hold DGX as of Q2 2023.

Central Bank & Trust reported no remaining Quest Diagnostics position as of Q2 2023 after selling out during the quarter.
Central Bank & Trust sold 7 Quest Diagnostics shares in Q2 2023, an estimated $990.
Central Bank & Trust first reported a position in Quest Diagnostics in Q1 2023 and held it in 1 quarter.
Central Bank & Trust's Quest Diagnostics position peaked at $990 in Q1 2023.
818 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2023.

Based on Central Bank & Trust's 13F filing for Q2 2023, filed 13 Jul 2023.